Koers Rasna Therapeutics, Inc. Other OTC
Aandelen
RASP
US7538881068
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 15,44 mln. 14,2 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | - 0 | Nettowinst (verlies) 2023 | -4 mln. -3,68 mln. | EV/omzet 2022 | - |
Nettoschuld 2022 | 180K 166K | Nettoschuld 2023 | 136K 125K | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-1,98
x | K/w-verhouding 2023 |
-2
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 14,81% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Keeren Shah
DFI | Director of Finance/CFO | 47 | 01-07-16 |
Jules S. Jacob
PRN | Corporate Officer/Principal | - | 01-07-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Brancaccio
BRD | Director/Board Member | 76 | 01-08-16 |
Willy Simon
CHM | Chairman | 72 | 14-10-20 |
Gary Jacob
BRD | Director/Board Member | 77 | 23-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 115 mld. | |
+11,84% | 106 mld. | |
-1,05% | 21,96 mld. | |
-14,15% | 21,84 mld. | |
-5,29% | 19,21 mld. | |
-4,16% | 18,08 mld. | |
-38,29% | 17,71 mld. | |
+7,99% | 14,32 mld. | |
+36,24% | 12,42 mld. |